{
  "0TB.F": {
    "city": "George Town",
    "country": "Cayman Islands",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Theravance Biopharma, Inc.",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "THERAVANCE BIOPHARMA",
    "state": null,
    "summary": "Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio also comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; TD-8236, an investigational, inhaled lung-selective pan-JAK inhibitor, which is Phase II clinical study for treatment of a range of inflammatory diseases; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. The company was incorporated in 2013 and is based in George Town, the Cayman Islands.",
    "website": "http://www.theravance.com",
    "zipcode": "KY1-1104"
  },
  "4139.TWO": {
    "city": "George Town",
    "country": "Cayman Islands",
    "currency": "TWD",
    "exchange": "TWO",
    "industry": "Medical Care Facilities",
    "long_name": "Ma Kuang Healthcare Holding Limited",
    "market": "tw_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MA KUANG HEALTHCARE HOLDING LIM",
    "state": null,
    "summary": "Kuang Healthcare Holding Limited, an investment holding company, provides medical services in Taiwan. The company offers TCM healthcare services, such as TCM orthopedic, weight management, pain management, examination, and TCM aftercare services; and TCM consultation, acupuncture, TuiNa therapy, cupping, Gua Sha/Scrapping, and TDP lamp services. It also provides Chinese medicinal powders, healthcare products, and Chinese proprietary medicines. The company operates 20 TCM clinics and TuiNa centres. Kuang Healthcare Holding Limited was founded in 2009 and is headquartered in George Town, the Cayman Islands.",
    "website": "http://www.makuanggroup.com",
    "zipcode": null
  },
  "6541.TW": {
    "city": "George Town",
    "country": "Cayman Islands",
    "currency": "TWD",
    "exchange": "TAI",
    "industry": "Biotechnology",
    "long_name": "Tanvex BioPharma, Inc.",
    "market": "tw_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "TANVEX BIOPHARMA INC",
    "state": null,
    "summary": "Tanvex BioPharma, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar and biologic products and drugs in Taiwan and the United States. Its products pipeline include TX01, which has completed phase III clinical trials; TX05, which is in phase III clinical trials for the treatment of cancer; TX16 which is in phase I; and other products. The company was formerly known as Ruenvex Biotech, Inc. Tanvex BioPharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.",
    "website": "http://www.tanvex.com",
    "zipcode": "KY1-1205"
  },
  "8406.TWO": {
    "city": "Grand Cayman",
    "country": "Cayman Islands",
    "currency": "TWD",
    "exchange": "TWO",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Ginko International Co., Ltd.",
    "market": "tw_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "GINKO INTERNATIONAL CO LTD",
    "state": null,
    "summary": "Ginko International Co., Ltd., together with its subsidiaries, manufactures and sells non-disposable and disposable contact lenses, and lens care products in China, Germany, the United Kingdom, Australia, Poland, Canada, Brazil, Iran, and internationally. The company offers various optical products, such as high definition contact lenses, toric lenses, cosmetic lenses, and others, as well as lens solutions under the Horien and Hydron brands. Ginko International Co., Ltd. was founded in 2007 and is based in Grand Cayman, the Cayman Islands.",
    "website": "http://www.ginkointernational.com",
    "zipcode": "KY1-1205"
  },
  "MITO": {
    "city": "George Town",
    "country": "Cayman Islands",
    "currency": "USD",
    "exchange": "NGM",
    "industry": "Biotechnology",
    "long_name": "Stealth BioTherapeutics Corp",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Stealth BioTherapeutics Corp.",
    "state": null,
    "summary": "Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.",
    "website": "http://www.stealthbt.com",
    "zipcode": "KY1-9005"
  },
  "S1BA.F": {
    "city": "George Town",
    "country": "Cayman Islands",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Stealth BioTherapeutics Corp",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "STEALTH BIOTH. SP.ADR/12",
    "state": null,
    "summary": "Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.",
    "website": "http://www.stealthbt.com",
    "zipcode": "KY1-9005"
  },
  "TBPH": {
    "city": "George Town",
    "country": "Cayman Islands",
    "currency": "USD",
    "exchange": "NGM",
    "industry": "Biotechnology",
    "long_name": "Theravance Biopharma, Inc.",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Theravance Biopharma, Inc.",
    "state": null,
    "summary": "Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio also comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; TD-8236, an investigational, inhaled lung-selective pan-JAK inhibitor, which is Phase II clinical study for treatment of a range of inflammatory diseases; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. The company was incorporated in 2013 and is based in George Town, the Cayman Islands.",
    "website": "http://www.theravance.com",
    "zipcode": "KY1-1104"
  }
}
